期刊文献+

甲状腺乳头状微小癌多灶性病变预测中央区淋巴结转移

Multifocal papillary thyroid microcarcinoma increases the risk of central lymph node metastasis
原文传递
导出
摘要 目的探讨甲状腺乳头状微小癌(papillary thyroid microcarcinoma,PTMC)中央区淋巴结转移(central lymph node metastasis, CLNM)的预测因素。方法回顾性分析2013年1月至2016年1月浙江省肿瘤医院头颈外科行中央区淋巴结清扫手术的PTMC 2 511例。单因素采用卡方检验,多因素采用二分类Logistic回归分析,分析年龄、性别、肿瘤大小、多灶性、腺外侵犯和伴有结节性甲状腺肿等因素与CLNM的相关性。结果单因素分析中,年龄、性别、肿瘤大小、多灶性、腺外侵犯和伴有结节性甲状腺肿等因素差异具有统计学意义。年龄〈45岁(P〈0.001,χ2=17.442),性别为(P〈0.001,χ2=17.029),肿瘤〈5 mm(P〈0.001,χ2=70.164.),腺外侵犯因素(P〈0.001,χ2=63.197)。伴有结节性甲状腺肿因素(P=0.017,χ2=5.611)。其中多灶因素差异具有统计学意义(P〈0.001,χ2=39.454)。多因素分析中:≥2个病灶PTMC的出现CLNM的风险是单灶PTMC的1.587倍。在多灶病变PTMC中≥3个病灶是2个病灶出现中央区淋巴结转移的近3倍(OR=2.730)。肿瘤〉5 mm(OR=1.926),伴有腺外侵犯(OR=1.606)。结论多灶性、肿瘤大小和腺外侵犯是PTMC出现CLNM的主要预测因素。其中≥3个以上的多灶是显著的预测因素。PTMC中央区淋巴结清扫的手术指征除了考虑肿瘤大小、腺外侵犯等常规因素外,尚需考虑多灶性因素。 ObjectiveTo investigate the predictive factors for central lymph node metastasis (CLNM) in papillary thyroid microcarcinoma (PTMC) .MethodsA retrospective study including 2511 cases of PTMC admitted from Jan. 2013 to Jan. 2016 were enrolled in our study. Chi-square test was used in univariate analysis. Logistic regression analysis was applied for multivariate analysis. The relation between age, sex, tumor size, multifocality, thyroidal extension, nodular goiter and central lymph node metastasis is analyzed.ResultsUnivariate analysis showed that age, sex, tumor size, multifocality, thyroidal extension and nodular goiter had statistical significance. Age less than 45 (P〈0.001, χ2=17.442) ; Male gender (P〈0.001, χ2=17.029) ; Tumor size less than 5 mm (P〈0.001, χ2=70.164.) ; Extrathyroid extension factor (P〈0.001, χ2=63.197) ; Nodular hyperplasia factor (P=0.017, χ2=5.611) . Multivariate analysis showed there was a significant relationship between multifocality and the central lymph node positivity. The odds ratio (OR) was 1.587 in patients with tumor foci ≥2 (P〈0.001) . While OR increased sharply near to 3 in patients withtumor foci ≥3 (OR=2.730) . Tumor size (OR=1.926) ; Extrathyroid extension (OR=1.606) .ConclusionsMultifocalty, tumor size and thyroidal extension are the main predicative factors for central lymph node metastasis in PTMC. Among them, tumor foci≥3 is an important predictor. Besides the conventional factors such as tumor size, thyroidal extension etc, multifocalty should also be taken into consideration.
作者 郑伟慧 王可敬 吴军舟 王文栋 赏金标 Zhe ng Weihui;Wang Kejing;Wu Junzhou;Wang Wendong;Shang Jinbiao(Department of Head and Neck Surgery,Zhejiang Cancer Hospital,Hangzhou 310022,China;Institution of Cancer Research,Zhejiang Cancer Hospital,Hangzhou 310022,China)
出处 《中华内分泌外科杂志》 CAS 2018年第4期286-290,共5页 Chinese Journal of Endocrine Surgery
基金 浙江省自然科学基金资助项目(LQ14H160002、LY15H160008)
关键词 甲状腺乳头状微小癌 中央区淋巴结 转移 多灶 Papillary thyroid microcarcinomas Central compartment lymph node Metastasis Multifocality
  • 相关文献

参考文献3

二级参考文献64

  • 1Arem R, Padayatti S, Saliby AH, et al. Thyroid mierocarcinoma: prevalence, prognosis, and management[ J]. Endocrine Practise, 1999,5:148-156.
  • 2Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002[J]. JAMA,2006,295(18) :2164-2167.
  • 3Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association Management Guidelines for patients with thy- roid nodulesand differentiated thyroid cancer[J]. Thyroid,2009, 19(11) :1167-1214.
  • 4Ito Y, Miyauchi A, Inoue H, et al. An observational trim ibr pa- pillary thyroid microcarcinoma in Japanese patients [ J ]. World J Surg,2010 ,34 :28-35.
  • 5American Thyroid Association (ATA) Guidelines Taskforce on Thy- roid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association manage- ment guidelines for patients with thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2009, 19(11):1167-1214.
  • 6Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid as- sociation management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid as- sociation guidelines task force on thyroid nodules and differentiat- ed thyroid cancer[J]. Thyroid, 2016, 26(1):1-133.
  • 7Tuttle RM, Haddad RI, Ball DW, et al. Thyroid carcinoma, version 2.2014[J]. J Natl Compr Canc Netw, 2014, 12(12):1671-1680.
  • 8Xing MZ. Molecular pathogenesis and mechanisms of thyroid can- cer[J]. Nat Rev Cancer, 2013, 13(3):184-199.
  • 9De Biase D, Gandolfi G, Ragazzi M, et al. TERT promoter mutations in papillary thyroid microcarcinomas[J]. Thyroid, 2015, 25(9):1013- 1019.
  • 10Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1):28-35.

共引文献391

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部